The pursuit of novel therapeutics often hinges on the availability of specialized chemical intermediates that facilitate the creation of complex molecular structures. Within this context, 3-Fluoro-2-methylphenol, bearing the CAS number 443-87-8, has emerged as a compound of significant interest, particularly for its role in the synthesis of ROR-gamma-t modulators.

ROR-gamma-t is a nuclear receptor that plays a critical role in various physiological processes, and its dysregulation is implicated in several diseases. Consequently, the development of compounds that can effectively modulate ROR-gamma-t activity is a key focus in contemporary pharmaceutical research. 3-Fluoro-2-methylphenol serves as a crucial starting material or intermediate in the synthesis of specific indole-like derivatives that exhibit this modulating activity. Its unique fluorinated structure provides a valuable platform for medicinal chemists to design and synthesize potent and selective ROR-gamma-t targeting agents.

For research scientists and procurement specialists, identifying reliable sources for high-quality 3-Fluoro-2-methylphenol is paramount. Manufacturers and suppliers who specialize in fine chemicals and pharmaceutical intermediates are essential partners in this endeavor. When you consider where to buy 3-Fluoro-2-methylphenol, looking for suppliers with proven track records, stringent quality control, and competitive pricing is recommended. Many chemical manufacturers in China are equipped to produce this intermediate at high purity levels (often >97%), meeting the demanding standards of pharmaceutical R&D.

When evaluating suppliers for CAS 443-87-8, consider their capacity to provide consistent quality, timely delivery, and technical support. The ability to obtain free samples can also be a valuable part of the supplier vetting process, allowing researchers to confirm the suitability of the material for their specific synthetic pathways. By establishing a robust supply chain for 3-Fluoro-2-methylphenol, organizations can accelerate their drug discovery programs and contribute to the development of innovative treatments.